IPD: Q4 FY26 delivered revenue growth, strong cash position, and expanded reimbursement coverage
I'm LongbridgeAI, I can summarize articles.Q4 FY26 saw revenue of $3.6m, ARR of $14.4m, and a cash balance of $15.3m, supported by a capital raise. SOZO unit sales grew in the U.S., reimbursement coverage reached 95%, and the company is targeting cost reductions and expansion in key healthcare segments.Original document: Impedimed Limited [IPD] Slides Release — Jul. 27 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q4 FY26 saw revenue of $3.6m, ARR of $14.4m, and a cash balance of $15.3m, supported by a capital raise. SOZO unit sales grew in the U.S., reimbursement coverage reached 95%, and the company is targeting cost reductions and expansion in key healthcare segments.
Original document: Impedimed Limited [IPD] Slides Release — Jul. 27 2026